Clinical Trials Sponsored by Oystershell NV

Total 334 results

Galapagos NV

Completed

GLPG0259 in Methotrexate-refractory Rheumatoid Arthritis

Rheumatoid Arthritis

Belgium, Netherlands, Poland, Russian Federation, Ukraine
Galapagos NV

Completed

Oral Bioavailability of Two Solid Formulations of GLPG0259.

Healthy

Belgium
Galapagos NV

Completed

First-in-Human Single Ascending Subcutaneous (s.c.) Dose and Single Oral Dose of GLPG0187

Healthy

Belgium
Fugeia NV

Completed

In Vivo Evaluation of the Physiological Effects of Arabinoxylan-oligosaccharides (AXOS) in Healthy Subjects (Juniors)

Healthy Subjects | Gastrointestinal Health

Belgium
Indigo Diabetes NV

Completed

The SHINE Study: Safety of Implant and Preliminary Performance of the SHINE SYSTEM in Diabetic Subjects

Diabetes Mellitus, Type 2 | Diabetes Mellitus | Hypoglycemia | Diabetes Mellitus, Type 1 | Ketoacidosis, Diabetic | Hyperglycaemia (Diabetic)

Belgium, Slovenia, France
Biocartis NV
AstraZeneca

Withdrawn

EGFR_IUO 3.20 Clinical Study Protocol

NSCLC
Chiesi SA/NV

Unknown

Adherence Evaluation in COPD

COPD | Adherence, Treatment

Belgium
Biotronik Belgium NV

Completed

BIOFLOW-III Belgium Satellite Registry

Myocardial Ischemia | Coronary Artery Disease

Belgium
ABSCINT NV/SA

Not yet recruiting

HER2 Targeted Molecular Imaging in mBC Using 68Ga-ABS011 (HERMIA)

Metastatic Breast Cancer

Belgium
Flamingo Therapeutics NV

Recruiting

Activity and Safety of Danvatirsen and Pembrolizumab in HNSCC (PEMDA-HN)

HNSCC

United States, Korea, Republic of
Chiesi SA/NV

Terminated

Study in COPD Patients Evaluating the Quality of Life (TRISNOOZE) (TRISNOOZE)

Chronic Obstructive Pulmonary Disease

Belgium
Chiesi SA/NV

Completed

Fixed Dose Triple Therapy in Severe Chronic Obstructive Pulmonary Disease in a Real World Setting (TRIVOLVE)

Chronic Obstructive Pulmonary Disease

Belgium
Chiesi SA/NV

Enrolling by invitation

Observational Study to Assess the Quality of Life in Nephropathic Cystinosis Patients (PROREAL)

Nephropathic Cystinosis

Belgium
Hilbert Paradox NV

Completed

Study to Verify the Feasibility of Collecting a Broad Variety of Individual Health Data

Healthy

Belgium
KU Leuven
Qompium NV

Not yet recruiting

The Effect of a Case-finding App on the Detection Rate of Atrial Fibrillation in Primary Care Patients

Atrial Fibrillation Paroxysmal
Janssen-Cilag International NV

Active, not recruiting

A Study to Evaluate Further Therapeutic Strategies With Guselkumab in Participants With Moderate-to-Severe Plaque-Type Psoriasis (GUIDE)

Psoriasis

Germany, France
Janssen-Cilag International NV

Active, not recruiting

A Study to Assess the Treatment of Schizophrenia With Paliperidone Palmitate in Rwandan Healthcare Settings (CASPAR)

Schizophrenia

Rwanda
Galapagos NV
Gilead Sciences

Active, not recruiting

Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis (SELECTIONLTE)

Ulcerative Colitis

United States, Netherlands, Israel, Spain, Taiwan, Australia, Italy, Hong Kong, Singapore, Korea, Republic of, Canada, Germany, United Kingdom, New Zealand, Ireland, Poland, Romania, Croatia, Belgium, Japan, India, Malaysia, Sweden, F... and more
Novosanis NV
Universiteit Antwerpen

Withdrawn

Investigation of Urinary Biomarkers for the Detection of Prostate Cancer (URODETECT-WP2)

Prostate Cancer | Urine | Liquid Biopsy

Belgium
Janssen-Cilag International NV

Completed

A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in Participants With Treatment Resistant Major Depressive Disorder (ESCAPE-TRD)

Depressive Disorder, Major

Israel, Hungary, Korea, Republic of, Taiwan, Portugal, Turkey, Germany, Malaysia, Denmark, Bulgaria, Czechia, Belgium, Poland, Brazil, Netherlands, Argentina, Finland, Greece, South Africa, Austria, Kazakhstan, Norway, Sweden, United...
Janssen-Cilag International NV

Terminated

A Study of Orally Administered Pimodivir in Adult Participants With Renal Impairment

Kidney Failure, Chronic

Germany
Gilead Sciences
Galapagos NV

Terminated

Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Are Naive to Biologic DMARD Therapy (PENGUIN 1)

Psoriatic Arthritis

Korea, Republic of, United States, Taiwan, Australia, Canada, Japan, Poland, Spain, New Zealand, Czechia, Hungary, Bulgaria, Russian Federation
Gilead Sciences
Galapagos NV

Completed

Study to Evaluate the Efficacy and Safety of Filgotinib in the Treatment of Perianal Fistulizing Crohn's Disease (Divergence2)

Fistulizing Crohn's Disease

United States, Italy, Belgium, Austria, Canada, Hungary, United Kingdom, Germany, France
Gilead Sciences
Galapagos NV

Terminated

Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Have an Inadequate Response or Are Intolerant to Biologic DMARD Therapy (PENGUIN 2)

Psoriatic Arthritis

Korea, Republic of, United States, Australia, Belgium, Canada, Czechia, Hungary, Japan, Poland, Spain, Taiwan
Gilead Sciences
Galapagos NV

Terminated

Study to Evaluate the Efficacy and Safety of Filgotinib in Adults With Active Noninfectious Uveitis (HUMBOLDT)

Noninfectious Uveitis

United States, Israel, United Kingdom, Germany, Australia, Canada, New Zealand
Gilead Sciences
Galapagos NV

Completed

Study to Evaluate the Efficacy and Safety of Filgotinib in the Treatment of Small Bowel Crohn's Disease (SBCD) (DIVERGENCE 1)

Small Bowel Crohn's Disease

United States, Belgium, United Kingdom, Germany, Spain, Czechia, Canada, Austria, France, Hungary, Italy, Ukraine
Gilead Sciences
Galapagos NV

Completed

Filgotinib Versus Placebo in Adults With Active Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Biologic Disease-modifying Anti-rheumatic Drug(s) (DMARDs) Treatment (FINCH 2)

Rheumatoid Arthritis

United States, France, Germany, Spain, Israel, Japan, Korea, Republic of, Belgium, Argentina, Poland, Hungary, United Kingdom, Mexico, Australia, Switzerland
Janssen-Cilag International NV

Completed

A Study to Determine the Epidemiology and Evaluate the Burden of Disease in Respiratory Syncytial Virus/Human Metapneumovirus and Influenza A Infected Hospitalized Participants (Adults and Children)

Respiratory Tract Infections

Germany, Spain
Janssen-Cilag International NV

Withdrawn

A Study of Esketamine Nasal Spray Plus a New Standard-of-care Oral Antidepressant or Placebo Nasal Spray Plus a New Standard-of-care Oral Antidepressant in Adult and Elderly Participants With Treatment-resistant Depression

Depressive Disorder, Treatment-Resistant
Janssen-Cilag International NV

Completed

A Survey to Collect Treatment Experience Feedback From Patients, Physicians, Nurses and Carers After Switching to Paliperidone Palmitate 3-monthly

Schizophrenia

Germany, Spain, Belgium, Hungary, France, Italy, United Kingdom
Janssen-Cilag International NV

Completed

A Study to Investigate P2X7 Receptor Occupancy by JNJ-54175446 With the Newly Developed P2X7 Receptor Positron Emission Tomography (PET) Tracer 18F-JNJ-64413739

Healthy

Belgium
Janssen-Cilag International NV

Completed

A Study in Healthy Participants to Evaluate the Effects of Multiple Doses of JNJ-55308942 on Cytochrome P450 Substrate Activity and on the Pharmacokinetics of Levonorgestrel/Ethinyl Estradiol

Healthy

Belgium
Janssen-Cilag International NV

Completed

A Phase 1 Study to Evaluate the Effect of the Organic Anion Transporter Inhibitor Probenecid on the Pharmacokinetics of JNJ-64041575 in Healthy Adults

Healthy

Germany
Janssen-Cilag International NV

Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-48816274

Healthy

United Kingdom
Janssen-Cilag International NV

Completed

A Study to Evaluate the Effect of Multiple Oral Doses of JNJ-42847922 on the Steady-state Pharmacokinetics of an Oral Contraceptive Containing Ethinyl Estradiol and Levonorgestrel in Healthy Female Adult Participants

Healthy

Belgium
Galapagos NV
MorphoSys AG

Completed

First in Human of Single and Multiple Doses of MOR106

Healthy | Dermatitis, Atopic

Belgium, Hungary, Moldova, Republic of, Romania
Janssen-Cilag International NV

Completed

A Single Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-42165279 in Healthy Male Participants

Healthy Volunteers | Pharmacokinetics

Belgium
Janssen-Cilag International NV

Completed

A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-42847922 in Healthy Participants

Healthy

Germany
Janssen-Cilag International NV

Completed

An Observational Study to Evaluate Tolerability of Canagliflozin and Sulphonylurea in Type 2 Diabetes Patients During Ramadan (CRATOS)

Diabetes Mellitus, Type 2

United Arab Emirates, Lebanon, Kuwait
Janssen-Cilag International NV

Completed

Observational Study (This Means That no Drug is Tested) in Patients Suffering of Gastroesophageal Reflux Disease. (PROFILE)

Gastroesophageal Reflux Disease | GERD | Gastro-oesophageal Reflux | Gastro-Esophageal Reflux | Esophageal Reflux
Janssen-Cilag International NV

Completed

Pilot Study to Evaluate the Duration of Effects on Simulated Car Driving and Cognitive Performance After a Single Dose of JNJ-42847922, Zolpidem and Placebo in Healthy Participants

Healthy

Netherlands
Janssen-Cilag International NV

No longer available

Early Access Program of Telaprevir With Peginterferon and Ribavirin in Chronic Hepatitis C Subjects

Hepatitis C

Australia, Belgium, Germany, Spain, Switzerland, Romania, Serbia, Greece, New Zealand, Brazil, Russian Federation, Austria, Hungary, Czech Republic, Luxembourg
Janssen-Cilag International NV

Completed

Open-Label, Bridging Study of Telaprevir in Treatment-Naïve and Treatment-Experienced Russian Patients With Genotype 1 Chronic Hepatitis C

Genotype 1 Chronic Hepatitis C

Russian Federation
Therabel Pharma SA/NV

Completed

Effect of Molsidomine on the Endothelial (Internal Layer of Blood Vessels) Dysfunction in Patients With Angina Pectoris (MEDCOR)

Atherosclerosis | Stable Angina Pectoris

Belgium
Janssen-Cilag International NV

Completed

A Study to Compare the Pharmacodynamics of Canagliflozin and Dapagliflozin in Healthy Volunteers

Healthy

Germany
Janssen-Cilag International NV

Completed

InORS - International Observational Registry on Schizophrenia With Injectable Risperidone and Oral Antipsychotics

Schizophrenia

France, Germany, Spain, South Africa, Turkey, Greece, Czech Republic, Russian Federation
Janssen-Cilag International NV

Completed

Effects of Canagliflozin on C-peptide Clearance in Healthy Volunteers

Healthy

Germany
Janssen-Cilag International NV

Completed

A Safety, Tolerability, Pharmacokinetics, and Immunogenicity Study of CNTO 6785 in Healthy Volunteers

Healthy

Belgium
Janssen-Cilag International NV

Completed

A Clinical Trial Comparing the Tolerability of Etravirine to Efavirenz in Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Treatment-naive HIV-1 Infected Patients (SENSE)

Acquired Immunodeficiency Syndrome | HIV Infection | HIV

France, United Kingdom, Germany, Spain, Switzerland, Israel, Russian Federation, Austria, Hungary, Romania, Denmark
Janssen-Cilag International NV

Completed

Treatment Simplification by Darunavir/Ritonavir 800/100 mg Once a Day Versus a Triple Combination Therapy With Darunavir/Ritonavir (MONET)

HIV Infections | Human Immunodeficiency Virus | Acquired Immunodeficiency Syndrome Virus | AIDS Virus

United Kingdom, Belgium, Germany, Spain, Portugal, Israel, Denmark, Russian Federation, Austria, Hungary, Switzerland

3

Subscribe